Colloidal carriers and blood–brain barrier (BBB) translocation: A way to deliver drugs to the brain?

Abbott, 1996, Transporting therapeutics across the blood–brain barrier, Mol. Med. Today, 2, 106, 10.1016/1357-4310(96)88720-X Adams, 2003, Amphiphilic block copolymers for drug delivery, J. Pharm. Sci., 92, 1343, 10.1002/jps.10397 Alakhov, 1999, Block copolymer-based formulation of doxorubicin From cell screen to clinical trials, Colloids Surf. B: Biointerfaces, 16, 113, 10.1016/S0927-7765(99)00064-8 Allen, 1999, Nano-engineering block copolymer aggregates for drug delivery, Colloids Surf. B: Biointerfaces, 16, 3, 10.1016/S0927-7765(99)00058-2 Alyautdin, 1997, Delivery of loperamide across the blood–brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles, Pharm. Res., 14, 325, 10.1023/A:1012098005098 Alyaudtin, 2001, Interaction of poly(butylcyanoacrylate) nanoparticles with the blood–brain barrier in vivo and in vitro, J. Drug Target, 9, 209, 10.3109/10611860108997929 Artzner, 2000, Lipid-DNA and lipid-polyelectrolyte mesophases: structure and exchange kinetics, Cell. Mol. Biol. (Noisy-le-grand), 46, 967 Aubert-Pouessel, 2004, In vitro study of GDNF release from biodegradable PLGA microspheres, J. Contr. Release, 95, 463, 10.1016/j.jconrel.2003.12.012 Badger, 1999, Citrobacter freundii invade and replicates in human brain microvascular endothelial cells, Infect. Immun., 67, 4208, 10.1128/IAI.67.8.4208-4215.1999 Bagger, 2004, The potential of nasal application for delivery to the central brain a microdialysis study of fluorescenin in rats, Eur. J. Pharm. Sci., 21, 235, 10.1016/j.ejps.2003.10.012 Banks, 2001, B.: Transport of human immunodeficiency virus type1 pseudoviruses across the blood–brain barrier: role of envelope proteins and adsortive endocytosis, J. Virol., 75, 4681, 10.1128/JVI.75.10.4681-4691.2001 Barratt, 2001, Polymeric micro-and nanoparticles as drug carriers, 753 Bartus, 1996, Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7, Exp. Neurol., 142, 14, 10.1006/exnr.1996.0175 Batrakova, 2001, Mechanism of pluronic effect on P-glycoprotein efflux system in blood–brain barrier: contributions of energy depletion and membrane fluidization, J. Pharmacol. Exp. Ther., 299, 483 Batrakova, 2001, Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies, J. Pharmacol. Exp. Ther., 296, 551 Benoit, 2000, Development of microspheres for neurological disorders: from basics to clinical applications, J. Contr. Release, 65, 285, 10.1016/S0168-3659(99)00250-3 Bickel, 2001, Brain-specific drug targeting strategies, 23 Black, 2004, Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor, Cancer Contr., 11, 165, 10.1177/107327480401100304 Bobardt, 2004, Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion, J. Virol., 78, 6567, 10.1128/JVI.78.12.6567-6584.2004 Bodor, 1999, Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems, Adv. Drug Deliv. Rev., 36, 229, 10.1016/S0169-409X(98)00090-8 Bolton, 1998, Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood–brain barrier breakdown in vivo, Neuroscience, 86, 1245, 10.1016/S0306-4522(98)00058-X Borchard, 1994, Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers, Int. J. Pharm., 110, 29, 10.1016/0378-5173(94)90372-7 Borlongan, 2003, Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport, Brain Res. Bull., 60, 297, 10.1016/S0361-9230(03)00043-1 Brigger, 2002, Nanoparticles in cancer therapy and diagnosis, Adv. Drug Deliv. Rev., 54, 631-L651, 10.1016/S0169-409X(02)00044-3 Brigger, 2002, Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting, J. Pharmacol. Exp. Ther., 303, 928, 10.1124/jpet.102.039669 Calvo, 2001, PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases, J. Neurosci. Meth., 111, 151, 10.1016/S0165-0270(01)00450-2 Calvo, 2001, Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery, Pharm. Res., 18, 1157, 10.1023/A:1010931127745 Calvo, 2002, Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat, Eur. J. Neurosci., 15, 1317, 10.1046/j.1460-9568.2002.01967.x Chamberlain, 1997, Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases, J. Neurosurg., 87, 694, 10.3171/jns.1997.87.5.0694 Chauhan, 2002, Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain, Antisense Nucl. Acid Drug Dev., 12, 353, 10.1089/108729002761381320 Chou, 1998, D.: Lidocaine distribution into the CNS following nasal and arterial delivery: a comparison of local sampling and microdialysis techniques, Int. J. Pharm., 171, 53, 10.1016/S0378-5173(98)00170-7 Chow, 2001, Direct nose–brain transport of benzoylecgonine following intranasal administration in rats, J. Pharm. Sci., 90, 1729, 10.1002/jps.1122 Cloughesy, 1999, Intra-arterial cereport (RMP-7) and carboplatin: a dose escalation study for recurrrent malignant gliomas, Neurosurgery, 44, 270, 10.1097/00006123-199902000-00015 da Cruz, 2004, Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons, Exp. Neurol., 187, 65, 10.1016/j.expneurol.2003.12.013 Dahlin, 2000, Transfer of dopamine in the olfactory pathway following nasal administration in mice, Pharm. Res., 17, 737, 10.1023/A:1007542618378 Dai, 2001, Glioma models, Biochim. Biophys. Acta, 1551, M19 Davis, 1997, Biomedical applications of nanotechnology—implications for drug targeting and gene therapy, Trends Biotechnol., 15, 217, 10.1016/S0167-7799(97)01036-6 Fattal, 2002, Nanoparticles as drug delivery systems, 1864 Fiala, 1997, TNF-alpha opens a paracellular route for HIV-1 invasion across the blood–brain barrier, Mol. Med., 3, 553, 10.1007/BF03401701 Fiorillo, 2004, Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors, J. Neurooncol., 66, 179, 10.1023/B:NEON.0000013471.53015.52 Fisher, 2002, Potential new methods for antiepileptic drug delivery, CNS Drugs, 16, 579, 10.2165/00023210-200216090-00001 Fournier, 2003, Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats, Cancer, 97, 2822, 10.1002/cncr.11388 Fournier, 2003, Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma, Int. J. Pharm., 268, 31, 10.1016/j.ijpharm.2003.08.014 Friese, 2000, Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system, Eur. J. Pharm. Biopharm., 49, 103, 10.1016/S0939-6411(99)00073-9 Gabizon, 1992, Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes, Cancer Res., 52, 891 Gelperina, 2002, Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma, Toxicol. Lett., 126, 131, 10.1016/S0378-4274(01)00456-8 Groll, 2000, Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system, J. Infect. Dis., 182, 274, 10.1086/315643 Grondin, 2003, Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases, Prog. Drug Res., 61, 101 Guerin, 2004, Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers, Invest. New Drugs, 22, 27, 10.1023/B:DRUG.0000006172.65135.3e Hashizume, 2002, Increased endothelial vesicular transport correlates with increased blood-tumor barrier permeability induced by bradykinin and leukotriene C4, J. Neuropathol. Exp. Neurol., 61, 725, 10.1093/jnen/61.8.725 Hau, 2004, Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma, Cancer, 100, 1199, 10.1002/cncr.20073 Huang, 2001, Cellular mechanisms of microbial proteins contributing to invasion of the blood–brain barrier, MicroRev. Cell Microbiol., 3, 277, 10.1046/j.1462-5822.2001.00116.x Hughes, 1993, clinicopathologic study of 100 cases of Parkinson's disease, Arch. Neurol., 50, 140, 10.1001/archneur.1993.00540020018011 Huwyler, 1996, Brain drug delivery of small molecules using immunoliposomes, Proc. Natl. Acad. Sci. U.S.A., 93, 14164, 10.1073/pnas.93.24.14164 Illum, 2000, Transport od drugs from the nasal cavity to the central nervous system, Eur. J. Pharm. Sci., 11, 1, 10.1016/S0928-0987(00)00087-7 Illum, 2004, Is nose-to-brain transport of drugs in man a reality?, J. Pharm. Pharmacol., 53, 3, 10.1211/0022357022539 Jollivet, 2004, Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease, Biomaterials, 25, 933, 10.1016/S0142-9612(03)00601-X Jones, 1999, Polymeric micelles—a new generation of colloidal drug carriers, Eur. J. Pharm. Biopharm., 48, 101, 10.1016/S0939-6411(99)00039-9 Kabanov, 1992, New clases of drug carries: micelles of poly(oxyethylene)–poly(oxypropylene) block copolymers as microcontainers for drug targeting form blood in brain, J. Contr. Release, 22, 141, 10.1016/0168-3659(92)90199-2 Kabanov, 2004, New technologies for drug delivery across the blood brain barrier, Curr. Pharm. Design, 10, 1355, 10.2174/1381612043384826 Kono, 2000, Design of fusogenic liposomes using a poly(ethylene glycol) derivative having amino grups, J. Contr. Release, 68, 225, 10.1016/S0168-3659(00)00263-7 Koukourakis, 2000, High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas—rationale for combination with radiotherapy, Acta Oncol., 39, 207, 10.1080/028418600430789 Kreuter, 1992, Nanoparticles: preparation and applications, 123 Kreuter, 1995, Passage of peptides through the blood–brain barrier with colloidal polymer particles (nanoparticles), Brain Res., 674, 171, 10.1016/0006-8993(95)00023-J Kreuter, 2002, Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood–brain barrier, J. Drug Target, 10, 317, 10.1080/10611860290031877 Kreuter, 2003, Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles, Pharm. Res., 20, 409, 10.1023/A:1022604120952 Lindner, 1998, Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing cell line in rodent and primate models of Parkinson's disease, Cell Transplant, 7, 165, 10.1016/S0963-6897(97)00169-3 Liu, 2000, Analysis of human immnodeficiency virus type 1 gp 160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain, J. Neurolvirol., 6, S70 Liu, 2002, Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway, J. Virol., 76, 6689, 10.1128/JVI.76.13.6689-6700.2002 Lo, 2001, Drug delivery to damaged brain, Brain Res. Brain Res. Rev., 38, 140, 10.1016/S0165-0173(01)00083-2 Mackinc, 1998, Human blood–brain barrier receptors for Alzheimer's amyloid-b 1–40, J. Clin. Invest., 102, 734, 10.1172/JCI2029 Martin, 2001, Tight junction and their role in cancer metastasis, Histol. Histopathol., 16, 1183 Matsuo, 2000, Efficient introduction of macromolecules and oligonucleotides into brain capillary endothelial cells using HVJ-liposomes, J. Drug Target, 8, 207, 10.3109/10611860008997899 McIntosch, 1998, Molecular and cellular sequelae of experimental traumatic brain injury: pathogenetic mechanisms, Neuropathol. Appl. Neurobiol., 24, 251, 10.1046/j.1365-2990.1998.00121.x Menei, 2004, Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma, Cancer, 100, 405, 10.1002/cncr.11922 Miller, 2002, Breaking down barriers, Science, 297, 1116, 10.1126/science.297.5584.1116 Misra, 2003, Drug delivery to the central nervous system: a review, J. Pharm. Pharm. Sci., 6, 252 Mizuno, 2002, Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models, Cancer Gene Ther., 9, 825, 10.1038/sj.cgt.7700503 Neuwelt, 1979, Osmotic blood–brain barrier disruption Computerized tomographic monitoring of chemotherapeutic agent delivery, J. Clin. Invest., 64, 684, 10.1172/JCI109509 Neuwelt, 2004, Mechanisms of disease: the blood–brain barrier, Neurosurgery, 54, 131, 10.1227/01.NEU.0000097715.11966.8E Norimoto, 2003, Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-b gene vector and dendritic cells, Cancer Gene Ther., 10, 549, 10.1038/sj.cgt.7700598 Noseworthy, 2000, Multiple sclerosis, N. Engl. J. Med., 343, 938, 10.1056/NEJM200009283431307 Olivier, 1999, Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity, Pharm. Res., 16, 1836, 10.1023/A:1018947208597 Omori, 2003, Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin, Neurol. Res., 25, 275, 10.1179/016164103101201508 Owens, 1995, The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis, Mult. Scler., 13, 51 Papadopoulos, 2001, Emerging molecular mechanisms of brain tumor oedema, Br. J. Neurosurg., 15, 101, 10.1080/02688690120036775 Papadopoulos, 2001, Occludin expression in microvessels of neoplastic and non-neoplastic human brain, Neuropathol. Appl. Neurobiol., 27, 384, 10.1046/j.0305-1846.2001.00341.x Pardridge, 1995, Transport of small molecules through the blood–brain barrier: biology and methodology, Adv. Drug Deliv. Rev., 15, 5, 10.1016/0169-409X(95)00003-P Pardridge, 2002, Blood–brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins, Adv. Exp. Med. Biol., 513, 397, 10.1007/978-1-4615-0123-7_15 Peracchia, 1998, Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer, Pharm. Res., 15, 550, 10.1023/A:1011973625803 Peracchia, 1999, Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting, J. Contr. Release, 60, 121, 10.1016/S0168-3659(99)00063-2 Peracchia, 1999, Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles, Biomaterials, 20, 1269, 10.1016/S0142-9612(99)00021-6 Persidsky, 1999, Microglial and astrocyte chemokines regulate monocyte migration through the blood–brain barrier in human immunodeficiency virus-1 encephalitis, Am. J. Pathol., 155, 1599, 10.1016/S0002-9440(10)65476-4 Petty, 2002, Junctional complexes of the blood–brain barrier: permeability changes in neuroinflammation, Prog. Neurobiol., 68, 311, 10.1016/S0301-0082(02)00128-4 Polman, 1988, Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis, J. Neuroimmunol., 17, 209, 10.1016/0165-5728(88)90069-0 Ring, 1998, Pneumococcal trafficking across the blood–brain barrier: molecular analysis of a novel bidirectional pathway, J. Clin. Invest., 102, 347, 10.1172/JCI2406 Roessler, 1994, Direct plasmid mediated transfection of adult murine brain cells in vivo using cationic liposomes, Neurosci. Lett., 167, 10.1016/0304-3940(94)91015-4 Saito, 2004, Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging, Cancer Res., 64, 2572, 10.1158/0008-5472.CAN-03-3631 Schlageter, 1999, Microvessel organization and strcuture in experimental brain tumors: microvessel population with distinctive structural and functional properties, Microvasc. Res., 58, 312, 10.1006/mvre.1999.2188 Schmidt, 2003, Intravenous liposomal prednisolone downregulates in situ TNF-alpha production by T-cells in experimental autoimmune encephalomyelitis, J. Histochem. Cytochem., 51, 1241, 10.1177/002215540305100915 Schmidt, 2003, Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis, Brain, 126, 1895, 10.1093/brain/awg176 Schroeder, 1998, Efficacy of oral dalargin-loaded nanoparticle delivery across the blood–brain barrier, Peptides, 19, 777, 10.1016/S0196-9781(97)00474-9 Shangguan, 1998, Cation-dependent fusogenicity of an N-acyl phosphatidylethanolamine, Biochim. Biophys. Acta, 68, 225 Shi, 2001, Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes, Pharm. Res., 18, 1095, 10.1023/A:1010910523202 Shoichet, 2000, Cell delivery to the central nervous system, Adv. Drug Deliv. Rev., 42, 81, 10.1016/S0169-409X(00)00055-7 Siegal, 1995, Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy, J. Neurosurg., 83, 1237, 10.3171/jns.1995.83.6.1029 Steiniger, 2004, Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles, Int. J. Cancer, 109, 759, 10.1002/ijc.20048 Sugawa, 1998, An antisense EGFR oligonucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro, J. Neuro-Oncol., 39, 237, 10.1023/A:1005903002865 Temsamani, 2000, Brain drug delivery technologies: novel approaches for transporting therapeutics, PSTT, 3, 2000 Terasaki, 1999, The blood–brain barrier efflux transporters as a detoxifying system for the brain, Adv. Drug Deliv. Rev., 36, 195, 10.1016/S0169-409X(98)00088-X Tsao, 2002, Development of hematogenous pneumococcal meningitis in adult mice: the role of TNF-[alpha], FEMS Immunol. Med. Microbiol., 32, 133 Vajkoczy, 2001, Vascular microenvironment in gliomas, J. Neuro-Oncol., 50, 99, 10.1023/A:1006474832189 van Laar, 1999, Future delivery systems for apomorphine in patients with Parkinson's disease, Adv. Neurol., 80, 535 Vinogradov, 1999, Poly(ethylene glycol)–polyethyleneimine nanogel particles: novel drug delivery systems for antisense oligonucleotides, Colloids Surf. B: Biointerfaces, 16, 291, 10.1016/S0927-7765(99)00080-6 Vinogradov, 2002, Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells, Adv. Drug Deliv. Rev., 54, 135, 10.1016/S0169-409X(01)00245-9 Vinogradov, 2004, Nanogels for oligonucleotide delivery to the brain, Bioconjug. Chem., 15, 50, 10.1021/bc034164r Wang, 2002, Local drug delivery to the brain, Adv. Drug Deliv. Rev., 54, 987, 10.1016/S0169-409X(02)00054-6 Wang, 1998, Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat, Biopharm. Drug Dispos., 19, 571, 10.1002/(SICI)1099-081X(199812)19:9<571::AID-BDD142>3.0.CO;2-O Wang, 2002, Role of OmpA and IbeB in Escherichia coli K1 invasion of brain microvascular endothelial cells in vitro and in vivo, Pediatric Res., 51, 559, 10.1203/00006450-200205000-00003 Witt, 2002, Pluronic p85 block copolymer enhances opioid peptide analgesia, J. Pharmacol. Exp. Ther., 303, 760, 10.1124/jpet.102.039545 Wolka, 2003, Pain and the blood–brain barrier: obstacles to drug delivery, Adv. Drug Deliv. Rev., 55, 987, 10.1016/S0169-409X(03)00100-5 Yoshida, 2003, Clinical gene therapy for brain tumors liposomal delivery of anticancer molecule to glioma, J. Neurooncol., 65, 261, 10.1023/B:NEON.0000003655.03671.fa Yoshida, 2004, Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes, Hum. Gene Ther., 15, 77, 10.1089/10430340460732472 Zhang, 2003, Global non-viral gene transfer to the primate brain following intravenous administration, Mol. Ther., 7, 11, 10.1016/S1525-0016(02)00018-7 Zhang, 2003, Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes, Pharm. Res., 20, 1779, 10.1023/B:PHAM.0000003375.13655.f9 Zhang, 2004, Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer, Clin. Cancer Res., 10, 3667, 10.1158/1078-0432.CCR-03-0740 Zhu, 2004, Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice, J. Gene Med., 6, 906, 10.1002/jgm.575 Zlokovic, 1997, Can blood–brain barrier play a role in the development of cerebral amyloids and Alzheimer's disease pathology?, Neurobiol. Dis., 4, 23, 10.1006/nbdi.1997.0134